IMMUNE NETWORK

The Korean Association of Immunobiologists (대한면역학회)
권호 표지

The Effect of Mesenchymal Stem Cells on the Activation of Dendritic Cells in the Cell Culture Insert System

세포배양삽입체계(Cell Culture Insert System)에서 중간엽 줄기세포(Mesenchymal Stem Cell)가 수지상세포(Dendritic Cell)의 활성화에 미치는 영향

  • Kim, Kee Won (Department of Internal Medicine, Medical College, The Catholic University of Korea) ;
  • Park, Suk Young (Department of Internal Medicine, Medical College, The Catholic University of Korea) ;
  • Lee, Kyung Bock (Future Cell Bank) ;
  • Kim, Hyun-su (Future Cell Bank)
  • 김기원 (가톨릭대학교 의과대학 내과학교실) ;
  • 박석영 (가톨릭대학교 의과대학 내과학교실) ;
  • 이경복 (퓨처셀뱅크) ;
  • 김현수 (퓨처셀뱅크)
  • Published : 2004.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Bone marrow mesenchymal stem cells (MSC) inhibit the immune response of lymphocytes to specific antigens and dendritic cells (DC) are professional antigenpresenting cells whose function is to present antigen to naive T-lymphocytes with high efficiency and play a central role in the regulation of immune response. We studied the effects of MSC on DC to evaluate the relationship between MSC and DC in transplantation immunology. Methods: MSC were expanded from the bone marrow and DC were cultured from peripheral blood mononuclear cells (PBMNC) of 6 myelogenous leukemia after achieving complete response. Responder cells isolated from PBMNC and lysates of autologous leukemic cells are used as tumor antigen. The effect of MSC on the DC was analyzed by immunophenotype properties of DC and by proliferative capacity and the amount of cytokine production with activated PBMNC against the allogeneic lymphocytes. Also, cytotoxicity tests against leukemic cells studied to evaluate the immunologic effect of MSC on the DC. Results: MSC inhibit the CD83 and HLA-class II molecules of antigen-loaded DC. The proliferative capacity and the amount of INF-$\gamma$ production of lymphocytes to allogeneic lymphocytes were decreased in DC co-cultured with MSC. Also the cytotoxic activity of lymphocytes against leukemic cells was decreased in DC co-cultured with MSC. Conclusion: MSC inhibit the activation and immune response of DC induced by allogeneic or tumor antigen.

Keywords

Acknowledgement

Supported by : 가톨릭대학교 대전성모병원 임상의학연구소

References

  1. Deans RJ, Moseley AB: Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol 28;875-884, 2000 https://doi.org/10.1016/S0301-472X(00)00482-3
  2. Reyes M, Lund T, Lenvik T, Aular D, Koodie L, Verfaillie CM:Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98;2615-2625, 2001 https://doi.org/10.1182/blood.V98.9.2615
  3. Graf T: Differentiation plasticity of hematopoietic cells. Blood 99;3089-3101, 2002 https://doi.org/10.1182/blood.V99.9.3089
  4. Herzog EL, Chai Li, Krause DS: Plasticity of marrow-derived stem cells. Blood 102;3483-3493, 2003 https://doi.org/10.1182/blood-2003-05-1664
  5. Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R: Mesenchymal stem cells distribute to a w ide range of tissues following systemic infusion into nonhuman primates. Blood 101;2999-3001, 2003 https://doi.org/10.1182/blood-2002-06-1830
  6. Korbling M, Estrov Z: Adult stem cells for tissue repair-a new therapeutic concept? N Eng J Med 349;570-582, 2003 https://doi.org/10.1056/NEJMra022361
  7. Deng Y, Guo X, Yuan Q, Li S: Efficiency of adenovirus vector mediated CTLA4Ig gene delivery into mesenchymal stem cells. Chin Med J 116;1649-1654, 2003
  8. Noort WA, Krusselbrink AB, in't Anker PS, Kruger M, van Bezooijen RL, de Paus RA, Heemskerk MHM, Lowik CWGM, Falkenburg JHF, Willemze R, Fibbe WE: Mesenchymal stem cells promote engraftment of human umbilical cord bloodderived CD34(+) cells in NOD/SCID mice. Exp Hematol 30;870-878, 2002 https://doi.org/10.1016/S0301-472X(02)00820-2
  9. Lee ST, Jang JH, Cheong J, Kim JS, Maemg H, Hahn JS, Ko YW, Min YH: Treatment of high-risk acute myelogenous leukaem ia by myeloablative chem oradiotherapy followed by coinfusion of T-cell-depleted haematopoietic stem cells and cultureexpanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br J Haematol 118;1128-1131, 2002 https://doi.org/10.1046/j.1365-2141.2002.03767.x
  10. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R: Mesenchymal stem cells suppress lymphocytes proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30;42-48, 2002 https://doi.org/10.1016/S0301-472X(01)00769-X
  11. Engleman EG: Dendritic cells: potential role in cancer therapy. Cytotechnology 25;1-8, 1997 https://doi.org/10.1023/A:1007997918593
  12. Austyn JM, Phil MA: Dendritic cells. Cur Opin Hematol 5;3-15, 1998 https://doi.org/10.1097/00062752-199801000-00002
  13. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G: Proliferation dendritic cell progenitors in human blood. J Exp Med 180;83-93, 1994 https://doi.org/10.1084/jem.180.1.83
  14. Weidmann F, Brieger J, Jahn B, Hoelzer D, Bergmann L, Mitrou PS: Lactate dehydrogenase-release assay: a reliable, nonradioactive technique for analysis of cytotoxic lymphocyte-mediated lytic activity against blasts from acute myelocytic leukemia. Ann Hematol 70;153-158, 1995 https://doi.org/10.1007/BF01682036
  15. Slavin S, Morecki S, Weiss L, Shapira MY, Resnick I, Or R:Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy-from bench to patient bedside. Semin Oncol 31;4-21, 2004 https://doi.org/10.1053/S0093-7754(04)00224-6
  16. Devine SM, Peter S, Martin BJ, Barry F, McIintosh KR:Mesenchymal stem cells: stealth and suppression. Cancer J 7;s76-82, 2001
  17. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM: Human bone marrow stromal cells suppress T-lymphocyte proliferation induce by cellular or nonspecific mitogenic stimuli. Blood 99;3838-3843, 2002 https://doi.org/10.1182/blood.V99.10.3838
  18. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, Dazzi F: Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101;3722-3729, 2003 https://doi.org/10.1182/blood-2002-07-2104
  19. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57;11-20, 2003 https://doi.org/10.1046/j.1365-3083.2003.01176.x
  20. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH, Milpied N, Sutton L, Jouet JP, Attal M, Bordigoni P, Cahn JY, Sadoun A, Ifrah N, Guyotat D, Faucher C, Fegueux N, Reiffers J, Maraninchi D, Blaise D : Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLAidentical sibling transplantation. Leukemia 17;869-875, 2003 https://doi.org/10.1038/sj.leu.2402909
  21. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C: Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102;3837-3844, 2003 https://doi.org/10.1182/blood-2003-04-1193